V. Hingorani

Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma

Friedrich Weber, Anthony L. Asher, Richard D. Bucholz et al. · Journal of Neuro-Oncology · 2003 · 199 citations

Medicine, Immunology, Oncology +12

Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia

R. Fleischmann, Bradley M. Kerr, Li‐Tain Yeh et al. · Lara D. Veeken · 2014 · 104 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma

Friedrich Weber, Frank Floeth, Anthony L. Asher et al. · 2003 · 84 citations

Medicine, Oncology, Pharmacotherapy +17

Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males

Zancong Shen, Colin Rowlings, Brad Kerr et al. · Drug Design Development and Therapy · 2015 · 55 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16

Phase 2a Randomized Controlled Trial of Short-Term Activity, Safety, and Pharmacokinetics of a Novel Nonnucleoside Reverse Transcriptase Inhibitor, RDEA806, in HIV-1-Positive, Antiretroviral-Naive Subjects

Graeme Moyle, Marta Boffito, Albrecht Stoehr et al. · Antimicrobial Agents and Chemotherapy · 2010 · 41 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17